| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05646459 Details | 2023-12-04 Interventional | 1 | 0 | Cannabidiol Chronic Periodo… Gingivitis Inflammation Periodontitis Inflammation Gu… Periodontitis, … | Study was unable to obtain IRB approval because CBD was not legal in Nebraska at that time. - | |||
| NCT05321940 Details | 2023-12-04 Interventional | 1 | 0 | Interferons Vaccines Leukemia Leukemia, Myelo… Leukemia, Myelo… Leukemia, T-Cel… Leukemia-Lympho… Precursor Cell … Acute Lymphobla… Acute Myelogeno… Adult T-Cell Le… Refractory Leuk… Relapsed Leukem… | Investigator decision - | |||
| NCT05111002 Details | 2023-12-04 Interventional | 1/2 | 12 | Doxycycline Lefamulin Mycoplasma Infe… Pleuropneumonia Mycoplasma Geni… | At Sponsor Request - | |||
| NCT04690855 Details | 2023-12-04 Interventional | 2 | 1 | Atezolizumab Talazoparib Breast Neoplasm… Triple Negative… Breast Cancer Triple Negative… | This study has been terminated due to Lack of Accrual. - | |||
| NCT03733067 Details | 2023-12-04 Interventional | 1/2 | 0 | Abatacept Anemia Cytopenia Leukopenia Thrombocytopeni… CTLA4 Haploinsu… Chronic Cytopen… | No enrollment - | |||
| NCT02420717 Details | 2023-12-04 Interventional | 2 | 11 | Antibodies Antibodies, Mon… Antineoplastic … BB 1101 Cortisone Cyclophosphamid… Cytarabine Dasatinib Daunorubicin Dexamethasone Dexamethasone a… Doxorubicin Immunoglobulins Leucovorin Liposomal doxor… Mercaptopurine Methotrexate Prednisone Rituximab Vincristine Leukemia Leukemia, Lymph… Philadelphia Ch… Precursor Cell … Recurrence Recurrent B Acu… Recurrent Ph-Li… Refractory B Ac… Refractory Ph-L… | Study was closed early due to low accrual and lack of response. - | |||
| NCT00752479 2009-012350-20 Details | 2023-12-04 Interventional | 1/2 | 4 | Basiliximab Cyclosporine Cyclosporins Methylprednisol… Methylprednisol… Methylprednisol… Mycophenolic Ac… Prednisolone Prednisolone ac… Prednisolone he… Prednisolone ph… Thymoglobulin Kidney Transpla… | Necessity of major revision of the protocol - | |||
| NCT00592280 Details | 2023-12-04 Interventional | 1 | 7 | Pancreatin Pancrelipase Pancreatitis Pancreatitis, G… Graft Pancreati… | Logistic problems with adequately timely organ collection and transport - | |||
| NCT06153186 Details | 2023-12-01 Interventional | 2 | 9 | Flunarizine Epilepsies, Myo… Epilepsy Epilepsy, Absen… Myoclonic Epile… Childhood Absen… Juvenile Absenc… Juvenile Myoclo… | The enrollment wasn't as predicted. We didn't have enough numbers to show statistical
significance. - | |||
| NCT05676463 Details | 2023-12-01 Interventional | 2 | - | Androgen Antago… Androgens Ascorbic Acid Estrogens, Conj… Hormones Methyltestoster… Prostatic Neopl… Prostate Adenoc… Stage IIIB Pros… Stage IIIC Pros… | on hold due to pause of outside company - | |||
| NCT05157464 Details | 2023-12-01 Interventional | 4 | 0 | Losartan Arthrofibrosis | Study was not initiated, no participants enrolled. - | |||
| NCT03478956 2017-003649-10 Details | 2023-12-01 Interventional | 1 | 24 | Etrolizumab Colitis Colitis, Ulcera… Crohn Disease Ulcer Crohn's Disease Ulcerative Coli… | The study was terminated due to program discontinuation, based on mixed efficacy results in the
adult ulcerative colitis and Crohn's disease studies. There were no safety concerns. - | |||
| NCT02626455 2015-001088-38 Details | 2023-12-01 Interventional | 3 | 547 | Bendamustine Hy… Cyclophosphamid… Doxorubicin Prednisone Rituximab Vincristine Lymphoma Lymphoma, Non-H… | The study did not meet the primary endpoint. The addition of copanlisib to standard immunochemo
therapy did not improve progression-free survival compared to the control arm. Base on the
study results, company decided to terminate the study. - | |||
| NCT01559129 2010-023047-15 Details | 2023-12-01 Interventional | 2 | 23 | Pomalidomide Lung Diseases Lung Diseases, … Scleroderma, Di… Scleroderma, Lo… Scleroderma, Sy… Sclerosis Interstitial Lu… Sclerosis, Syst… Systemic Sclero… Systemic Sclero… | Enrollment was stopped early (see limitations and caveats section). Based upon interim analysis data, the study did not meet its primary endpoints for subjects who had completed blinded treatment. The IDMC recommended the study be stopped due to lack of efficacy and the sponsor agreed with this recommendation. | |||
| NCT03970837 Details | 2023-11-30 Interventional | 3 | 1764 | Tofacitinib Arthritis Arthritis, Rheu… | Only Asia cohort is early terminated.Limited efficacy demonstrated in the contRAst program does
not support a suitable benefit/risk profile for otilimab as a potential treatment for RA. GSK
has decided not to progress with regulatory submissions. - | |||
| NCT03819660 Details | 2023-11-30 Interventional | 2 | 13 | Amifampridine Atrophy Muscular Atroph… Muscular Atroph… Spinal Muscular… | Development of indication not being pursued The results of efficacy are limited to the assessment of quality of life using the INQoL. The premature interruption of the study determined that few patients had available data of INQoL from Month 6 onwards. | |||
| NCT03818672 Details | 2023-11-30 Interventional | 4 | 5 | Rifaximin Liver Diseases Severe Hepatic … | Study determined to be infeasible. - | |||
| NCT03605758 Details | 2023-11-30 Interventional | 3 | 51 | Ivermectin Communicable Di… Infections Strongyloidiasi… Strongyloides S… | The original study PI passed away. Primary and Study Completion dates revised to reflect last
participant examination date. - | |||
| NCT01994824 Details | 2023-11-30 Interventional | 2 | 70 | Antilymphocyte … Thymoglobulin Graft vs Host D… Graft-vs-host D… | The trend was observed toward higher mortality among the patients receiving the intervention
Thymoglobulin on day 8 after hematopoietic cell transplantation. - | |||
| NCT01135199 Details | 2023-11-30 Interventional | 2 | 0 | Pomalidomide Fibrosis Idiopathic Pulm… Pulmonary Fibro… | FDA did not accept sponsor's animal toxicology data to support proposed dosing. - |